Nov

5

2008

8:00—5:30 PM
The Kaiser Family Foundation’s Barbara Jordan Conference Center, 1330 G Street, NW, Washington, DC
,
EXTERNAL EVENT

Addressing the Threat of Drug Resistant TB: A Realistic Assessment of the Challenges

The IOM Forum on Drug Discovery, Development, and Translation 
is hosting a workshop on 
Addressing the Threat of Drug Resistant TB: 
A Realistic Assessment of the Challenges
  

The Kaiser Family Foundation’s Barbara Jordan Conference Center
1330 G Street, NW
Washington, DC, 20005

REGISTER ONLINE

WORKSHOP DRAFT AGENDA INCLUDED BELOW

 8:00 – 8:10   Objectives of the Workshop

Gail Cassell, Eli Lilly
Workshop Chair

8:10 – 9:40   Panel I: SETTING THE STAGE 
10 minute presentations followed by a 30 minute panel discussion

Moderator: Ken Castro, Centers for Disease Control and Prevention

Paul Nunn, World Health Organization
Global Incidence of MDR-TB

Yanis Ben AmorEarth Institute
Undereported Threat of MDR-TB in Africa

Gerald Friedland, Yale University
HIV/MDR-XDR-TB: Implications

Megan Murray, Brigham & Women's Hospital
Number of MDRTB & XDRTB Patients Receiving Treatment Today: Successes/Failures/Consequences

Gao Qian, Shanghai Medical College
Transmission of MDR-TB

Neel GandhiAlbert Einstein College of Medicine of Yeshiva University
Transmission of XDR-TB

9:40 – 10:00   Break

10:00 – 11:30   Panel II: HOW DID WE GET TO WHERE WE ARE TODAY: DIFFERENT PERSPECTIVES 
10 minute presentations followed by a 30 minute panel discussion

Moderator: Richard Chaisson, Johns Hopkins University

Ed Nardell, Brigham & Women's Hospital
Lack of Infection Control

John RidderhofCenters for Disease Control and Prevention
Laboratory Capacity: A Global Analysis

Sok Thim (by phone), Cambodian Health Committee
Drug and Health Care Delivery: Cambodian and Ethiopian Perspectives

Paul Zintl, Partners in Health
Drug Supply: The Stop TB Partnership Perspective.

Ruth Levine, Center for Global Development
Critical Role of Accurate Demand Forecasting: Lessons Learned from Malaria

11:30 – 12:30   Lunch

12:30 – 1:30   Panel III: A BLUEPRINT FOR ACTION

Moderator: Peter Cegielski, Centers for Disease Control and Prevention

Salmaan Keshavjee, Partners in Health
The Plan: From Powder to Patient

Discussants:
Carol Nacy, Sequella, Inc.
Iain Richardson, Eli Lilly
Sarita Shah, Albert Einstein College of Medicine of Yeshiva University
Charles Wells, Otsuka

1:30 – 3:00   Panel IV: ESSENTIAL BUILDING BLOCKS
10 minute presentations followed by a 20 minute panel discussion

Moderator: Leonard Sacks, Food and Drug Administration

Dale Nordenberg and Hamish Fraser, Brigham & Women's Hospital
Knowledge Management (IT): What do we need and what do we have?

David Persing, Cepheid and Charles Daitch, Akonni Biosystems
Point of Care Diagnostics: How close are we?

Ann Ginsberg, TB Alliance
TB Drug Development: Realities of the Pipeline

Ray Woosley, The Critical Path Institute
Critical Path for Parallel Development of TB Point of Care Diagnostic and Drug Development

Jeff MoeDuke University
What are the odds? Who will pay? What are the incentives?

3:00 – 3:15   Break

Tony Fauci, National Institute of Allergy and Infectious Diseases
Critical Role of Research and Public/Private Partnerships

4:00 – 5:15   Panel V: THE NEED FOR URGENCY
Fifteen minute presentations followed by 45 minutes of discussion

Moderator: Jim Kim, Partners in Health

Mark Harrington, Treatment Action Group
Lessons from HIV

Paul Farmer, Partners in Health
Lessons from MDR-TB

5:15 -0 5:30   SYNTHESIS & NEXT STEPS

Gail Cassell, Eli Lilly
Workshop Chair

5:30   Adjourn

Topics

Subscribe today to receive CGD’s latest newsletters and topic updates.
Subscribe